Last updated on April 2017

ADDIA Proof-of-Performance Clinical Study


Brief description of study

The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease. ADDIA clinical study is a multi-centre, non-interventional, prospective, proof-of-performance study with only one visit. About 800 well-characterized subjects will be recruited into 3 groups in 2:1:1 ratio, namely patients with Alzheimer's disease (AD), patients with non-AD neurodegenerative disease (NAD) and 200 control subjects (healthy as compared to their age). - 400 patients with Alzheimer's disease (AD), - 200 patients with non-Alzheimer's neurodegenerative diseases (NAD), - 200 controls (healthy as compared to their age).

Clinical Study Identifier: NCT03030586

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Frédéric Blanc, MD

Hopitaux Universitaires de Strasbourg
Strasbourg, France
  Connect »

Florence Pasquier, MD

Centre Hospitalier R gional Universitaire de Lille
Lille, France
  Connect »

Moira Marizzoni, PhD

IRCCS Centro San Giovanni di Dio Fatenenefratelli
Brescia, Italy
  Connect »

Jean-François Démonet, MD

Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
  Connect »

Hakan Gurvit, MD

Istanbul University Hospital
Istanbul, Turkey
  Connect »